The Experts below are selected from a list of 624 Experts worldwide ranked by ideXlab platform

Rudolf Schenker - One of the best experts on this subject based on the ideXlab platform.

  • efficacy of milbemax Milbemycin Oxime praziquantel in the treatment of dogs experimentally infected with crenosoma vulpis
    Veterinary Parasitology, 2013
    Co-Authors: Gary Conboy, Wolfgang Seewald, Andrea C Bourque, Lisa M Miller, Rudolf Schenker
    Abstract:

    Crenosoma vulpis, the fox lungworm, infects wild and domestic canids and is a cause of chronic respiratory disease in dogs in North America and Europe. The objective of this study was to determine the efficacy of Milbemycin Oxime (0.5mg/kg)/praziquantel (5mg/kg) (Milbemax; Novartis Animal Health, Inc.) against C. vulpis infection in a randomized, blinded, placebo-controlled study using experimentally infected dogs. Sixteen beagles (8 males, 8 females) were each given 100 infective third-stage larvae of C. vulpis. Fecal samples were examined for first-stage larvae by quantitative Baermann examination pre-exposure and at days 21, 28, 35, 42 and 49 post-infection (PI). All of the dogs were shedding larvae in the feces at 21 days PI. The dogs were randomly assigned to one of two groups. At 28 days PI, Group 1 (4 males, 4 females) received placebo only while Group 2 (4 males, 4 females) received a single treatment of Milbemycin Oxime (0.5mg/kg) and praziquantel (5mg/kg). The 16 dogs were euthanized and necropsied at 49 days PI. Lungs were removed, assessed for gross lesions (graded on a subjective scale 0-3 with 0 being normal) and C. vulpis were collected by lung-flush and counted. Samples of lung tissue were preserved for evaluation of histopathology and the lesions graded on a subjective scale (0-3 with 0 being normal). Gross and histopathology lesions were detected in all 8 untreated Group 1 dogs with mean subjective lesion scores of 1.8 ± 0.7 (range 1-3) and 3.0 ± 0.0 (range 3), respectively. Gross lesions were observed in 3/8 and histopathology lesions in all 8 of the treated Group 2 dogs with mean subjective lesion scores of 0.4 ± 0.5 (range 0-1) and 1.3 ± 0.4 (range 1-2), respectively. The mean (geometric) number for adult C. vulpis recovered in untreated dogs was 48.3 (range 25-70) compared with 0.65 (range 0-2) in animals treated with Milbemax. The resulting efficacy against C. vulpis was 98.7%. The number of C. vulpis was significantly lower for treated dogs than the burden in the untreated group (p=0.0002). A single dose of Milbemax (Milbemycin Oxime 0.5mg/kg+praziquantel 5mg/kg) was highly effective for the treatment of patent C. vulpis infection in dogs. A dosing interval for the prevention of clinical disease in dogs exposed to natural infections has not been established.

  • the efficacy of Milbemycin Oxime against pre adult spirocerca lupi in experimentally infected dogs
    Veterinary Parasitology, 2011
    Co-Authors: Rudolf Schenker, N J Archer, Ivan Gerard Horak, P Swart
    Abstract:

    Abstract The aim of this investigation was to determine the efficacy of Milbemycin Oxime in preventing the oesophageal encapsulation of Spirocerca lupi , following the experimental infection of dogs. Two studies were conducted which involved a total of 21 purpose-bred Beagles. Each dog was infected with approximately 40, third stage infective S. lupi larvae. The larvae were dissected from scarabaeid beetles that had been collected from areas endemic for spirocercosis. In the first study, Milbemycin Oxime (minimum dose 0.5 mg/kg body weight) was administered to seven dogs on day 30 post-infection. Seven other dogs served as untreated controls. In the second study, Milbemycin Oxime (also at a minimum dose of 0.5 mg/kg body weight) was administered to four of seven infected dogs on day 28 post-infection. Treatment was repeated at 14- or 28-day intervals. All of the dogs, from both studies, were euthanized 168 or 169 days after infection. All S. lupi were recovered, and lesions in the thoracic aorta and oesophagus were described and quantified. A single treatment with Milbemycin Oxime was 79.8% effective in preventing the establishment of S. lupi in the oesophagus. This treatment significantly ( p S. lupi within the oesophagus and the size of the oesophageal nodules. The efficacy of anthelmintic treatment was increased to 100% when repeat doses of Milbemycin Oxime were administered at 14- or 28-day intervals. These repeat treatments completely prevented the establishment of S. lupi within the oesophagus and thereby averted the development of oesophageal nodules. As expected, none of the treatment protocols reduced S. lupi related damage within the aorta because the administration of Milbemycin Oxime only began after the larvae had completed their first stage of migration.

  • the efficacy of Milbemycin Oxime against pre adult spirocerca lupi in experimentally infected dogs
    Veterinary Parasitology, 2011
    Co-Authors: Rudolf Schenker, N J Archer, Ivan Gerard Horak, P Swart
    Abstract:

    Abstract The aim of this investigation was to determine the efficacy of Milbemycin Oxime in preventing the oesophageal encapsulation of Spirocerca lupi , following the experimental infection of dogs. Two studies were conducted which involved a total of 21 purpose-bred Beagles. Each dog was infected with approximately 40, third stage infective S. lupi larvae. The larvae were dissected from scarabaeid beetles that had been collected from areas endemic for spirocercosis. In the first study, Milbemycin Oxime (minimum dose 0.5 mg/kg body weight) was administered to seven dogs on day 30 post-infection. Seven other dogs served as untreated controls. In the second study, Milbemycin Oxime (also at a minimum dose of 0.5 mg/kg body weight) was administered to four of seven infected dogs on day 28 post-infection. Treatment was repeated at 14- or 28-day intervals. All of the dogs, from both studies, were euthanized 168 or 169 days after infection. All S. lupi were recovered, and lesions in the thoracic aorta and oesophagus were described and quantified. A single treatment with Milbemycin Oxime was 79.8% effective in preventing the establishment of S. lupi in the oesophagus. This treatment significantly ( p S. lupi within the oesophagus and the size of the oesophageal nodules. The efficacy of anthelmintic treatment was increased to 100% when repeat doses of Milbemycin Oxime were administered at 14- or 28-day intervals. These repeat treatments completely prevented the establishment of S. lupi within the oesophagus and thereby averted the development of oesophageal nodules. As expected, none of the treatment protocols reduced S. lupi related damage within the aorta because the administration of Milbemycin Oxime only began after the larvae had completed their first stage of migration.

  • the efficacy of Milbemycin Oxime against pre adult spirocerca lupi in experimentally infected dogs
    Veterinary Parasitology, 2011
    Co-Authors: D J Kok, N J Archer, Ivan Gerard Horak, Rudolf Schenker, P Swart
    Abstract:

    The aim of this investigation was to determine the efficacy of Milbemycin Oxime in preventing the oesophageal encapsulation of Spirocerca lupi, following the experimental infection of dogs. Two studies were conducted which involved a total of 21 purpose-bred Beagles. Each dog was infected with approximately 40, third stage infective S. lupi larvae. The larvae were dissected from scarabaeid beetles that had been collected from areas endemic for spirocercosis. In the first study, Milbemycin Oxime (minimum dose 0.5mg/kg body weight) was administered to seven dogs on day 30 post-infection. Seven other dogs served as untreated controls. In the second study, Milbemycin Oxime (also at a minimum dose of 0.5mg/kg body weight) was administered to four of seven infected dogs on day 28 post-infection. Treatment was repeated at 14- or 28-day intervals. All of the dogs, from both studies, were euthanized 168 or 169 days after infection. All S. lupi were recovered, and lesions in the thoracic aorta and oesophagus were described and quantified. A single treatment with Milbemycin Oxime was 79.8% effective in preventing the establishment of S. lupi in the oesophagus. This treatment significantly (p<0.05) reduced both the number of S. lupi within the oesophagus and the size of the oesophageal nodules. The efficacy of anthelmintic treatment was increased to 100% when repeat doses of Milbemycin Oxime were administered at 14- or 28-day intervals. These repeat treatments completely prevented the establishment of S. lupi within the oesophagus and thereby averted the development of oesophageal nodules. As expected, none of the treatment protocols reduced S. lupi related damage within the aorta because the administration of Milbemycin Oxime only began after the larvae had completed their first stage of migration.

  • the use of Milbemycin Oxime in a prophylactic anthelmintic programme to protect puppies raised in an endemic area against infection with spirocerca lupi
    Veterinary Parasitology, 2010
    Co-Authors: E.j. Williams, N J Archer, Rudolf Schenker, Ivan Gerard Horak
    Abstract:

    Abstract Spirocerca lupi is primarily a parasite of dogs and other carnivores. Clinical signs of infection are regurgitation, vomiting, weight loss, coughing and dyspnoea. Sudden death can also occur due to a ruptured aortic aneurysm. In this study, the Eastern Cape Province of South Africa was identified as an area with a high prevalence of S. lupi. A subsequent investigation, to evaluate the efficacy of Milbemycin Oxime as a prophylactic agent for canine spirocercosis, involved 58 puppies that were raised in this area in accordance with local husbandry procedures. Approximately half of the puppies served as untreated controls. Puppies in the treatment group received Milbemycin Oxime (minimum dose of 0.5 mg/kg body weight) when they were between 2 and 6 weeks old. They then received five further treatments at approximately 28-day intervals. The treatment was orally administered in tablet form. After the sixth treatment, puppies from both the treated and control groups were euthanized and post-mortem examinations were performed. Twenty-four out of 27 dogs in the untreated control group had become infected by S. lupi. In comparison, only 19 out of 31 dogs in the treatment group had evidence of spirocercosis as demonstrated by aortic nodules. The prophylactic regimen reduced the severity of aortic lesions and prevented 86.5% of S. lupi from becoming established in the thoracic aorta. It also prevented 89.4% of S. lupi from becoming established in the oesophagus and significantly reduced the number of oesophageal nodules. Milbemycin Oxime markedly reduced the level and severity of S. lupi infection in treated puppies raised in an endemic area of South Africa. It deserves further evaluation as a potential prophylactic treatment for spirocercosis.

P. Junquera - One of the best experts on this subject based on the ideXlab platform.

  • Efficacy of a Milbemycin Oxime-praziquantel combination product against adult and immature stages of Toxocara cati in cats and kittens after induced infection
    Veterinary Parasitology, 2006
    Co-Authors: Rudolf Schenker, Dwight D Bowman, Christian Epe, R. Cody, Wolfgang Seewald, G. Strehlau, P. Junquera
    Abstract:

    Abstract Two studies were performed to examine the efficacy of Milbemycin Oxime against fourth-stage larvae or adults of Toxocara cati . In the study to determine efficacy against fourth-stage larvae, 20 domestic shorthair cats were inoculated with 500 embryonated eggs. Four weeks after inoculation, the animals were allocated to two groups, and cats in one group were treated with medicated tablets containing 4 mg Milbemycin Oxime and 10 mg praziquantel (MILBEMAX ® ) and cats in the other group with placebo tablets. Seven days after treatment the animals were euthanatized and necropsied for worm counting. The number of worms found was significantly ( p  = 0.0002) lower in cats treated with medicated tablets than in cats treated with placebo tablets. The reduction in the number of worms was 96.53%. In the study to determine efficacy against mature adult worms, 13 kittens were inoculated with T. cati embryonated eggs. On day 45 after inoculation and after the infection had been confirmed through faecal examinations for 11 out of the 13 animals, the 11 infected animals were allocated to two groups and treated as in the first study. Seven days after treatment, all animals were euthanatized and necropsied for worm counting. The number of worms found was significantly ( p  = 0.0043) lower in kittens treated with medicated tablets than in kittens treated with placebo tablets. The reduction in the number of worms was 95.90%. No adverse effects were recorded during either study. It is concluded that the Milbemycin Oxime–praziquantel tablets that were used are efficacious for the control of T. cati infections in cats.

  • comparative effects of Milbemycin Oxime based and febantel pyrantel embonate based anthelmintic tablets on toxocara canis egg shedding in naturally infected pups
    Veterinary Parasitology, 2006
    Co-Authors: Rudolf Schenker, R. Cody, G. Strehlau, D Alexander, P. Junquera
    Abstract:

    Abstract The effect of two treatment programmes on egg shedding in dogs naturally infected with Toxocara canis , one based on a Milbemycin Oxime–praziquantel–lufenuron combination (SENTINEL ® Spectrum; Group 1) and the other based on a febantel–pyrantel embonate–praziquantel combination (DRONTAL ® Plus; Group 2), was compared in a study involving 104 suckling pups from three different kennels. The animals in Group 1 were treated at a minimum Milbemycin Oxime dose of 0.5 mg/kg bw starting at 2 weeks of age and subsequently every 4 weeks until reaching 26 weeks of age. The animals in Group 2 were treated every 2 weeks from week 2 until week 12 of age and then once at week 26 at a minimum febantel and pyrantel embonate dose of 15.0 and 14.4 mg/kg bw, respectively. Toxocara egg counts were determined fortnightly starting at 2 weeks of age and continuing until 26 weeks of age for every pup. Any adverse drug event was recorded during the trial. Both treatment programmes significantly reduced the zoonotic Toxocara egg shedding and were well tolerated by the pups. The pups in Group 1 showed lower average faecal egg counts and were found more frequently shedding no eggs than the pups in Group 2.

  • Repeat Dose Tolerance of a Combination of Milbemycin Oxime and Praziquantel in Breeding and Lactating Queens
    2005
    Co-Authors: Rudolf Schenker, R. Cody, P. Junquera
    Abstract:

    Two groups of 15 queens each were treated with placebo or with medicated tablets containing a combination of Milbemycin Oxime and praziquantel (Milbemax ® ) at at least the highest recommended dose rate once weekly during pregnancy and lactation. The queens in each group and their kittens were submitted to periodic controls, including clinical assessments, weighing, and blood analysis for hematology and clinical chemistry. The reproductive performance of each individual queen also was assessed. The results demonstrate that the investigated tablets containing a combination of Milbemycin Oxime and praziquantel are well tolerated by queens and their kittens during pregnancy and lactation.

  • Efficacy of a single Milbemycin Oxime administration in combination with praziquantel against experimentally induced heartworm (Dirofilaria immitis) infection in cats
    Veterinary parasitology, 2004
    Co-Authors: Claudio Genchi, G. Buscher, D. Cavalleri, R. Cody, Graziano Pengo, Valeria Bucci, P. Junquera
    Abstract:

    Abstract The efficacy of a combination of Milbemycin Oxime and praziquantel in preventing the establishment of experimentally induced heartworm (Dirofilaria immitis) infection was investigated in a study involving 24 young domestic short-hair cats. The animals were inoculated with 50 infective larvae on day 0. Subsequently they were divided into two groups of 12 animals each. The animals in group 1 were treated once with medicated tablets containing 4 mg Milbemycin (minimum dose 2 mg/kg body weight) and 10 mg praziquantel (MILBEMAX®) on day 30 after infection. Cats in group 2 received placebo tablets on the same day. On day 183 post-infection a blood sample was taken from each animal before euthanasia and necropsy. The blood samples were tested for the presence of microfilariae and the necropsied animals were examined for the presence of adult worms. Microfilariae were not found in any of the investigated cats. No heartworms were found in the animals in group 1 (treated with medicated tablets). Out of the 12 placebo-treated cats 1 was heartworm-free, whereas all the others were found to be infected with 1–3 adult heartworms.

  • Efficacy of Milbemycin Oxime against fourth-stage larvae and adults of Ancylostoma tubaeforme in experimentally infected cats.
    Veterinary Record, 2004
    Co-Authors: E. Humbert-droz, G. Buscher, D. Cavalleri, P. Junquera
    Abstract:

    The efficacy of Milbemycin Oxime against fourth-stage (L4) larvae and adults of Ancylostoma tubaeforme was investigated in a trial involving 24 young domestic shorthair cats. The animals were inoculated with approximately 300 infective stage three (L3) larvae and divided into three groups. After 12 days, eight cats (group 1) were treated with medicated tablets containing 4 mg Milbemycin and 10 mg praziquantel to test the efficacy against L4 larvae; eight cats in group 2 were treated with the same tablets after 33 days to test the efficacy against adult worms; and eight cats in group 3 were treated with a placebo tablet. Faecal egg counts were determined periodically in each cat and after 40 or 41 days the number of worms in each animal was determined postmortem. The egg count reduction was determined by comparing the geometric mean numbers of eggs per gram of faeces in the placebo and medicated groups, and the worm reduction by comparing the geometric mean numbers of worms. The egg count reduction was more than 99 per cent in both treated groups, while the number of worms in groups 1 and 2 were reduced by 94.7 per cent and 99.2 per cent, respedively.

Frederic Beugnet - One of the best experts on this subject based on the ideXlab platform.

  • Preference of Dogs between Two Oral Formulations of Endectoparasiticides: NEXGARD SPECTRA r (Afoxolaner and Milbemycin Oxime) and Simparica Trio TM (Sarolaner, Moxidectin and Pyrantel)
    Open Journal of Veterinary Medicine, 2020
    Co-Authors: Nadège Perier, Doug Carithers, William Russel Everett, Phrutsamon Wongnak, Karine Chalvet-monfray, Sheila J. Gross, Frederic Beugnet
    Abstract:

    Pet owner compliance is essential for the success of veterinary healthcare strategies. As some parasites are zoonotic, consistent parasite control is an integral part of the One-Health strategy. Highly palatable formulations help ensure compliance, as they offer a positive experience for the dog and the owner. This study was conducted to ascertain if dogs exhibited a preference between two commercially available oral formulations of broad-spectrum endectoparasiticides, NexGard Spectra (afoxolaner and Milbemycin Oxime) and Simparica Trio (sarolaner, moxidectin and pyrantel). For four consecutive days, 100 healthy dogs were offered both products and consumption was recorded. If one product was more consumed than the other, it was defined as the preferred product. No adverse event was recorded throughout the study. A total of 358 chewable tablets were consumed over four study days; 78.5% of dogs voluntarily consumed NexGard Spectra (281 chews), while 21.5% of dogs voluntarily consumed Simparica Trio (77 chews, p p -16), resulting in a preference ratio of 17.75 to 1 for NexGard Spectra.

  • Preference of Dogs between Two Oral Formulations of Endectoparasiticides: NEXGARD SPECTRA ® (Afoxolaner and Milbemycin Oxime) and Simparica Trio TM (Sarolaner, Moxidectin and Pyrantel) Preference of Dogs between Two Oral Formulations of Endectoparasi
    Open Journal of Veterinary Medicine, 2020
    Co-Authors: Nadège Perier, Douglas Carithers, William Russel Everett, Sheila Gross, Phrutsamon Wongnak, Karine Chalvet-monfray, Frederic Beugnet
    Abstract:

    Pet owner compliance is essential for the success of veterinary healthcare strategies. As some parasites are zoonotic, consistent parasite control is an integral part of the One-Health strategy. Highly palatable formulations help ensure compliance, as they offer a positive experience for the dog and the owner. This study was conducted to ascertain if dogs exhibited a preference between two commercially available oral formulations of broad-spectrum endectoparasiticides, NexGard Spectra (afoxolaner and Milbemycin Oxime) and Simparica Trio (sarolaner, moxidectin and pyrantel). For four consecutive days, 100 healthy dogs were offered both products and consumption was recorded. If one product was more consumed than the other, it was defined as the preferred product. No adverse event was recorded throughout the study. A total of 358 chewable tablets were consumed over four study days; 78.5% of dogs voluntarily consumed NexGard Spectra (281 chews), while 21.5% of dogs voluntarily consumed Simparica Trio (77 chews, p < 0.01). Among 75 dogs which demonstrated a preference for a product, significantly more dogs preferred NexGard Spectra (94.7%) compared to Simparica Trio (5.3%) (p < 2.2 × 10 −16), resulting in a preference ratio of 17.75 to 1 for NexGard Spectra.

  • Efficacy of a Single Oral Administration of Afoxolaner Alone or in Combination with Milbemycin Oxime against Ixodes hexagonus Ticks in Dogs
    Open Journal of Veterinary Medicine, 2019
    Co-Authors: Wilfried Lebon, Diane Larsen, Pascal Dumont, Marielle Servonnet, Frederic Beugnet
    Abstract:

    The efficacy of afoxolaner (NexGard® and NexGard Spectra®, Boehringer-Ingelheim), administered once orally at the minimum recommended dose, was assessed in dogs experimentally infested with Ixodes hexagonus ticks. The study was a blinded, negative controlled clinical efficacy study using a randomized block design. Twenty-four Beagle dogs, 12 females and 12 males were enrolled. Dogs were randomly allocated either to the negative control group, or to one of the two treated groups. Infestations were performed with 50 adult I. hexagonus ticks on Days-2, 7 and 28. On Day 0, dogs in groups 2 and 3 were treated with NexGard® (afoxolaner) or NexGard Spectra® (afoxolaner + Milbemycin Oxime), respectively. Tick counts were conducted 48 hours after treatment (Day 2) and 48 hours after each subsequent infestation (Days 9 and 30). In both treated groups, afoxolaner was 100% effective against existing infestations (p < 0.0001). Regarding the re-infestations, the efficacy of afoxolaner was 100% on Day 9 for both products, 96.5% and 100% on Day 30 for NexGard® and NexGard Spectra® respectively. NexGard® and NexGard Spectra® chewable tablets administered once orally at the minimum recommended dose were highly effective against I. hexagonus infestations for the 4 weeks duration of the study.

  • efficacy of once monthly doses of oral afoxolaner and afoxolaner Milbemycin Oxime in a well controlled study for the treatment of canine generalized demodicosis
    Open Journal of Veterinary Medicine, 2018
    Co-Authors: Steffen Rehbein, Frederic Beugnet, Christa De Vos, Doug Carithers, Josephus J Fourie
    Abstract:

    The efficacy of oral treatment with chewable tablets containing afoxolaner 2.27% w/w (NexGard®, Merial, now part of Boehringer-Ingelheim) or 1.875% w/w of afoxolaner and 0.375% w/w Milbemycin Oxime (NexGard Spectra®, Merial, now part of Boehringer-Ingelheim) was each assessed in eight dogs diagnosed with generalized demodicosis in this parallel group designed, blinded, randomized, single center negative controlled, efficacy study. Afoxolaner at the therapeutic dose (as close as possible to 2.5 mg/kg) was administered to Group 2 dogs, and afoxolaner (as close as possible to 2.5 mg/kg) with Milbemycin Oxime at 0.5 mg/kg was administered to Group 3 dogs on Days 0, 28 and 56. All dogs were observed once daily for general health starting on Day -7 until Day 84. All dogs were clinically examined on Days -7, -2, 14, 28, 42, 56, 70 and 84. Dogs were weighed on Days -7, -2, 27, 55, and 84. Live mite counts (based on five scrapings per dog and occasion) and clinical assessments, including photographic documentation, were performed on Days -2, 28, 56 and 84. Three monthly treatments with NexGard or NexGard Spectra against generalized demodicosis in dogs were highly effective resulting in a 99.9% and 100% efficacy against mites, respectively. After treatment with NexGard, only three live mites were recovered in five scrapings in one dog on Day 84. After treatment with NexGard Spectra, no mites were recovered in any scraping on any dogs in this group by Day 84. Both treatments resulted in a marked reduction of skin lesions and >90% hair-regrowth at three months after the initial treatment. Reduction of live mite counts was consistent with reduction in the extent and severity of the skin changes. Although the arithmetic mean mite numbers in the negative control group decreased slightly during the study, infection persisted in 7 of the 8 control dogs until Day 84. Both treatment groups of dogs showed a marked improvement of the associated dermatologic signs with steady improvement over the three-month treatment period.

  • Efficacy of Once-Monthly Doses of Oral Afoxolaner and Afoxolaner/Milbemycin Oxime in a Well-Controlled Study for the Treatment of Canine Generalized Demodicosis
    Open Journal of Veterinary Medicine, 2018
    Co-Authors: Steffen Rehbein, Frederic Beugnet, Christa De Vos, Doug Carithers, Josephus J Fourie
    Abstract:

    The efficacy of oral treatment with chewable tablets containing afoxolaner 2.27% w/w (NexGard®, Merial, now part of Boehringer-Ingelheim) or 1.875% w/w of afoxolaner and 0.375% w/w Milbemycin Oxime (NexGard Spectra®, Merial, now part of Boehringer-Ingelheim) was each assessed in eight dogs diagnosed with generalized demodicosis in this parallel group designed, blinded, randomized, single center negative controlled, efficacy study. Afoxolaner at the therapeutic dose (as close as possible to 2.5 mg/kg) was administered to Group 2 dogs, and afoxolaner (as close as possible to 2.5 mg/kg) with Milbemycin Oxime at 0.5 mg/kg was administered to Group 3 dogs on Days 0, 28 and 56. All dogs were observed once daily for general health starting on Day -7 until Day 84. All dogs were clinically examined on Days -7, -2, 14, 28, 42, 56, 70 and 84. Dogs were weighed on Days -7, -2, 27, 55, and 84. Live mite counts (based on five scrapings per dog and occasion) and clinical assessments, including photographic documentation, were performed on Days -2, 28, 56 and 84. Three monthly treatments with NexGard or NexGard Spectra against generalized demodicosis in dogs were highly effective resulting in a 99.9% and 100% efficacy against mites, respectively. After treatment with NexGard, only three live mites were recovered in five scrapings in one dog on Day 84. After treatment with NexGard Spectra, no mites were recovered in any scraping on any dogs in this group by Day 84. Both treatments resulted in a marked reduction of skin lesions and >90% hair-regrowth at three months after the initial treatment. Reduction of live mite counts was consistent with reduction in the extent and severity of the skin changes. Although the arithmetic mean mite numbers in the negative control group decreased slightly during the study, infection persisted in 7 of the 8 control dogs until Day 84. Both treatment groups of dogs showed a marked improvement of the associated dermatologic signs with steady improvement over the three-month treatment period.

Laura Miranda Contreras - One of the best experts on this subject based on the ideXlab platform.

Melanie Lane - One of the best experts on this subject based on the ideXlab platform.